Akso Health Group's Days Sales Outstanding for the
six
months ended in Sep. 2025 was 53.77.
Akso Health Group's Days Inventory for the
six
months ended in Sep. 2025 was 5.5.
Akso Health Group's Days Payable for the
six
months ended in Sep. 2025 was 0.
Therefore, Akso Health Group's Cash Conversion Cycle (CCC) for the
six
months ended in Sep. 2025 was 59.27.
Akso Health Group (NAS:AHG) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Akso Health Group Cash Conversion Cycle Related Terms
Akso Health Group Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Akso Health Group's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AHG vs ACH, FOCL, YI: Cash Conversion Cycle Comparison
For the Medical Distribution subindustry, Akso Health Group's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akso Health Group Cash Conversion Cycle vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Akso Health Group's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Akso Health Group's Cash Conversion Cycle falls into.
Akso Health Group Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Akso Health Group's Cash Conversion Cycle for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akso Health Group (AHG) has a Cash Conversion Cycle of 59.27 as of Sep. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Akso Health Group and its competitors.
Is Akso Health Group's Cash Conversion Cycle too high?
Akso Health Group's current Cash Conversion Cycle is 59.27. The Medical Distribution industry median Cash Conversion Cycle is 55.95. Akso Health Group's value of 59.27 is 5.9% above this industry median. Overall, Akso Health Group has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Akso Health Group's Cash Conversion Cycle compare to ACH and FOCL?
Akso Health Group's Cash Conversion Cycle of 59.27 can be compared against companies in the Medical Distribution industry. The industry median Cash Conversion Cycle is 55.95. Akso Health Group's value of 59.27 is 5.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Distribution company?
The median Cash Conversion Cycle among Medical Distribution companies is 55.95, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akso Health Group's current Cash Conversion Cycle of 59.27 is 5.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Akso Health Group and its competitors. For the Medical Distribution industry, the median Cash Conversion Cycle is 55.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akso Health Group's current Cash Conversion Cycle is 59.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akso Health Group stock overvalued right now?
Based on GuruFocus' analysis, Akso Health Group (AHG) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.47, compared to a current price of $1.52 — trading 223.4% above its estimated fair value. The current Cash Conversion Cycle is 59.27 and 5.9% above the Medical Distribution industry median of 55.95. Akso Health Group's overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Akso Health Group (AHG), the current Cash Conversion Cycle is 59.27 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akso Health Group (AHG) Overvalued in 2026?
Based on GuruFocus' analysis, Akso Health Group stock appears to be overvalued.
The current stock price of $1.52 is trading 223.4% above its estimated GF Value™ of $0.47.
GuruFocus considers Akso Health Group to be Significantly Overvalued.
Key valuation signals for AHG:
Cash Conversion Cycle: 59.27
GF Value™: $0.47 vs. price of $1.52 (223.4% above fair value)
Industry Position: 5.9% above the Medical Distribution median
No single metric tells the full story. See the AHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
36GF Score
Get the complete analysis for AHG
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AHG has been successfully added to your 
